Estrogen deficiency-mediated osteoimmunity in postmenopausal osteoporosis.
Yao YaoXiaoyu CaiYue ChenMeng ZhangCaihong ZhengPublished in: Medicinal research reviews (2024)
Postmenopausal osteoporosis (PMO) is a common disease associated with aging, and estrogen deficiency is considered to be the main cause of PMO. Recently, however, osteoimmunology has been revealed to be closely related to PMO. On the one hand, estrogen deficiency directly affects the activity of bone cells (osteoblasts, osteoclasts, osteocytes). On the other hand, estrogen deficiency-mediated osteoimmunity also plays a crucial role in bone loss in PMO. In this review, we systematically describe the progress of the mechanisms of bone loss in PMO, estrogen deficiency-mediated osteoimmunity, the differences between PMO patients and postmenopausal populations without osteoporosis, and estrogen deficiency-mediated immune cells (T cells, B cells, macrophages, neutrophils, dendritic cells, and mast cells) activity. The comprehensive summary of this paper provides a clear knowledge context for future research on the mechanism of PMO bone loss.
Keyphrases
- bone loss
- bone mineral density
- estrogen receptor
- postmenopausal women
- dendritic cells
- replacement therapy
- end stage renal disease
- body composition
- healthcare
- newly diagnosed
- chronic kidney disease
- immune response
- peritoneal dialysis
- prognostic factors
- cell proliferation
- signaling pathway
- smoking cessation
- current status
- cell death
- regulatory t cells
- genetic diversity
- breast cancer risk
- soft tissue